Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach.
Clin Biochem. 2011 Apr; 44(5-6):377-85.CB

Abstract

OBJECTIVES

Parkinson's disease (PD) ranks the second among the neurodegenerative disorders. Proteins involved in Parkinson's disease (PD) have been investigated but none as the diagnostic markers in blood.

DESIGN AND METHODS

In this study, we applied a proteomic strategy, by utilizing two-dimensional electrophoresis and mass spectrometry, to analyze two sample pools of plasma from the healthy individuals and PD subjects.

RESULTS

IgGκL and human serum amyloid P component (SAP) were found differentially expressed between these pools. SAP level increased by approximately 5-fold in PD samples, and the ELISA procedure revealed a significant (P<0.001) increase in SAP concentration (65.9 ± 18.7μg/mL) in the plasma of PD subjects (healthy individuals, 35.0 ± 12.5μg/mL), with sensitivity of 94.1% and specificity of 87.5%.

CONCLUSION

Our results indicated a potential feasibility of plasma SAP as a marker to approach PD.

Links

Publisher Full Text

Authors+Show Affiliations

Chen HM
Graduate Institute of Applied Science and Engineering, Fu-Jen Catholic University, New Taipei City, Taiwan.
Lin CY
No affiliation info available
Wang V
No affiliation info available

MeSH

AgedAged, 80 and overBiomarkersCase-Control StudiesElectrophoresis, Gel, Two-DimensionalEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMass SpectrometryMiddle AgedParkinson DiseaseProteomicsSerum Amyloid P-Component

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21223953